Compare Sunrun Inc (RUN) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Sunrun (RUN) trades at $7.79, up 2.64% on the day, but remains in a bearish technical trend with strong selling pressure in moving averages. The stock shows attractive valuation metrics with P/E of 5.3 and P/B of 0.54, while consistently beating earnings expectations in recent quarters. Recent developments include a record 580 MW grid dispatch with Tesla and expanded partnerships for distributed computing solutions.

Despite positive analyst sentiment (62% buy ratings) and a $15.40 consensus price target representing 98% upside, RUN faces significant headwinds including negative operating cash flow, high debt levels (70.76% debt-to-asset ratio), and solar industry pressure from elevated borrowing costs. The stock trades near its analyst low target of $7.00, suggesting limited downside but requiring careful risk assessment.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.